Wegovy Pill Sales Don’t Live Up to Wall Street Obesity Hype
Novo Nordisk A/S raised its forecasts for the second time this year on a rosy outlook for its obesity and diabetes drugs, though the firm’s US shares fell as sales of the new Wegovy weight-loss pill failed to top analysts’ expectations.
This is a summary aggregated from Bloomberg Markets. Read the complete article on the original site:
Read full article at Bloomberg Markets
